A Phase II Trial of the Pan-Her Inhibitor Poziotinib, in Patients With HER2-positive Metastatic Breast Cancer Who Had Received at Least Two Prior HER2-directed Regimens: Results of the NOV120101-203 Trial

International Journal of Cancer - United States

doi 10.1002/ijc.31651